J. Schütte

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 955 citations

jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun

J. Schütte, Jean Viallet, Marion M. Nau et al. · Cell · 1989 · 487 citations

Jun-b Inhibits, Signal Transduction, Cell Regulation +11

Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene.

J. Schütte, J D Minna, M. J. Birrer · Proceedings of the National Academy of Sciences · 1989 · 251 citations · Full text

Immunology, Cell Proliferation, Cell Specialization +18

Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination.

M. Krismann, B Todt, J.‐M. Schröder et al. · Journal of Clinical Oncology · 1995 · 196 citations

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

Sebastian Bauer, Jörg T. Hartmann, Maike de Wit et al. · International Journal of Cancer · 2005 · 173 citations · Full text

Residual Disease, Metastatic Gist, Surgical Oncology +14